Skip to main content

Articles

Conference Highlights ASCO, Lung Cancer

Atezolizumab Extends Disease-Free Survival in PD-L1−Positive Early-Stage NSCLC

Phoebe Starr

Value-Based Care, Conference Highlights ASCO

Rapid Biosimilar Adoption Possible in Community Oncology Practice

Chase Doyle

Multiple Myeloma, Conference Highlights ASCO

New CAR T-Cell Therapy Produces Durable Responses in Relapsed or Refractory Multiple Myeloma

Wayne Kuznar

FDA Approvals, Leukemia, Lymphoma, Conference Highlights ASCO

Rylaze FDA Approved as Part of a Treatment Regimen for Pediatric Leukemia and Lymphoma

Cholangiocarcinoma, FDA Approvals, Conference Highlights ASCO

Truseltiq Second Targeted Therapy Approved for Metastatic Cholangiocarcinoma Harboring FGFR2 Alterations

FDA Approvals, Multiple Myeloma, Conference Highlights ASCO

FDA Approves Darzalex Faspro plus Pomalyst and Dexamethasone for Multiple Myeloma

FDA Approvals, Conference Highlights ASCO

FDA Approves Avapritinib for Advanced Systemic Mastocytosis

FDA Approvals, Conference Highlights ASCO

Pembrolizumab plus Lenvatinib Combination Receives Regular Approval for Advanced Endometrial Carcinoma

FDA Approvals, Urothelial Cancer, Conference Highlights ASCO

Padcev Receives Regular FDA Approval for Locally Advanced or Metastatic Urothelial Cancer

Melanoma, Conference Highlights ASCO

Novel LAG-3–Blocking Antibody plus Nivolumab Shows Promise as First-Line Treatment in Advanced Melanoma

Wayne Kuznar

14
15
16
17
18
19
20

Page 17 of 246
Results 161 - 170 of 2458